2016
Palliative Care for Pancreatic and Periampullary Cancer
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surgical Clinics Of North America 2016, 96: 1415-1430. PMID: 27865285, PMCID: PMC5119929, DOI: 10.1016/j.suc.2016.07.012.Peer-Reviewed Original ResearchConceptsMost patientsPalliative careGastric outlet obstructionRelief of painPancreatic cancer patientsAdvanced diseaseLocalized diseaseMultimodality therapyCeliac plexusOutlet obstructionPeriampullary cancerObstructive jaundiceCancer patientsPancreatic cancerPalliative techniquesPatientsCommon endpointCancerDiseaseReliefCareCare triangleFamily goalsJaundicePainLonger Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. American Journal Of Clinical Oncology 2016, 39: 18-26. PMID: 24351782, PMCID: PMC4061284, DOI: 10.1097/coc.0000000000000022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyCohort StudiesDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansInduction ChemotherapyMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsProportional Hazards ModelsRetrospective StudiesSex FactorsTime FactorsTreatment OutcomeConceptsAdvanced pancreatic cancerCycles of chemotherapyOverall survivalInduction chemotherapyPancreatic cancerMedian overall survivalRole of chemotherapyTreatment of LAPCUnresectable stage 3Better survival outcomesBetter overall survivalCombination of chemotherapyJohns Hopkins HospitalSensitization of tumorsConsolidative chemoradiationSubsequent chemoradiationCombination chemotherapyCumulative incidenceProspective studySurvival outcomesStandard treatmentDisease progressionChemoradiationRetrospective analysisChemotherapy
2015
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. Journal Of Immunotherapy 2015, 38: 1-11. PMID: 25415283, PMCID: PMC4258151, DOI: 10.1097/cji.0000000000000062.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPD-1 blockadeT cellsObjective responsePD-L1PDA patientsPD-1/PD-L1 blockadePD-1/PD-L1 pathwayCytotoxic T-lymphocyte antigen-4Effector T-cell infiltrationPD-1 antibody monotherapyPD-L1 antibody therapySingle-agent checkpoint inhibitorsT-lymphocyte antigen-4Tumor microenvironmentMurine pancreatic ductal adenocarcinomaAddition of vaccineCTLA-4 pathwayImmune suppressive cellsImmune-suppressive signalsPDA tumor microenvironmentPD-L1 blockadeLow-dose cyclophosphamideCD8 T lymphocytesPD-1 antibody
2014
A preclinical murine model of hepatic metastases.
Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L. A preclinical murine model of hepatic metastases. Journal Of Visualized Experiments 2014, 51677. PMID: 25285458, PMCID: PMC4378377, DOI: 10.3791/51677.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell Line, TumorDisease Models, AnimalFemaleLiver Neoplasms, ExperimentalMiceMice, Inbred C57BLNeoplasm TransplantationPancreatic NeoplasmsConceptsHepatic metastasesMurine modelNumerous murine modelsPreclinical murine modelsTumor immunology researchPancreatic tumor modelPancreatic tumor cellsMurine pancreatic tumor modelMetastatic diseaseClinical conditionsMetastatic processTumor modelTherapy testingTumor cellsCancer treatmentMetastasisHuman cancersImmunology researchLiverModel mimicsPatientsCancerDiseaseMiceA Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors
Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH. A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. Annals Of Surgery 2014, 259: 204-212. PMID: 23673766, PMCID: PMC4048026, DOI: 10.1097/sla.0b013e31828f3174.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsStaging systemSimple prognostic toolNeuroendocrine tumorsPrognostic toolStage IFive-year overall survival rateNonfunctional pancreatic neuroendocrine tumorsMain staging systemsAJCC stage ITumor staging systemOverall survival rateAmerican Joint CommitteeSingle-institution seriesKi-67 labelingPrognostic factorsSurvival prognosticationSingle institutionJoint CommitteeMultivariate analysisNatural historyComparison of reportsPatientsNeoplasmsSurvival
2012
Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas
Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2012, 255: 326-333. PMID: 22167000, PMCID: PMC3534752, DOI: 10.1097/sla.0b013e3182378a18.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryClone CellsFemaleHumansLaser Capture MicrodissectionLoss of HeterozygosityMaleMiddle AgedMutationNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRetrospective StudiesSequence Analysis, DNAConceptsMultifocal intraductal papillary mucinous neoplasmsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmMucinous neoplasmsClinicopathologic featuresPancreatic cancerClonal relationshipBranch duct lesionsCystic precursor lesionsFamilial pancreatic cancerKRAS gene mutationsIntermediate dysplasiaIndependent genetic alterationsDuct lesionsClinicopathological characteristicsInvasive cancerPrecursor lesionsPartial pancreatectomyPatientsNeoplasmsIntermediate gradeGene mutationsCancerGenetic alterationsMolecular analysis
2011
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2011, 118: 2674-2681. PMID: 21935914, PMCID: PMC3578343, DOI: 10.1002/cncr.26553.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaConditional survivalConditional survival estimatesActuarial survivalCurative intentPositive marginsSurvival estimatesDuctal adenocarcinomaResection of PDACPostoperative year 5Date of surgeryCox regression analysisPredictors of survivalTime of surgeryMedian survivalMargin statusWorse survivalHigher lymphKaplan-MeierTumor sizeLarge cohortPatientsMultivariate analysisLymphSurgeryLoss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas
Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology 2011, 24: 1237-1247. PMID: 21552209, PMCID: PMC3155013, DOI: 10.1038/modpathol.2011.74.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaE-cadherin expressionPancreatic adenocarcinomaDuctal adenocarcinomaIndependent predictorsPoor outcomeCox proportional hazards regression modelingProportional hazards regression modelingPancreatic cancer outcomesWorse median survivalResectable pancreatic adenocarcinomaMinority of patientsKaplan-Meier analysisE-cadherin statusMedian survivalSurgical resectionWorse prognosisCancer outcomesSubgroup analysisPathological factorsPatient outcomesCell adhesion moleculeMortality riskTissue microarrayPartial lossPresence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3493-3499. PMID: 21537863, PMCID: PMC3166423, DOI: 10.1245/s10434-011-1745-9.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaResection marginsTransection marginR0 resectionIntraepithelial neoplasiaPanIN lesionsPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsPancreatic resection marginPancreatic transection marginPresence of PanINOverall median survivalIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsSurgical marginsTyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer
Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei PB, Van Eyk JE, Maitra A, Laheru D, Jaffee EM. Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer. PLOS ONE 2011, 6: e19390. PMID: 21572519, PMCID: PMC3084841, DOI: 10.1371/journal.pone.0019390.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnnexin A2Antibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorBlotting, WesternCancer VaccinesCell Line, TumorCell MembraneCell MovementDisease-Free SurvivalEpithelial-Mesenchymal TransitionFemaleHumansLiverMiceMice, Inbred C57BLNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, ExperimentalPancreatic NeoplasmsPhosphorylationRNA InterferenceTumor Cells, CulturedTyrosineConceptsPancreatic ductal adenocarcinomaAnti-ANXA2 antibodiesPDA metastasisEpithelial-mesenchymal transitionAnnexin A2PDA cellsPost-treatment seraProlongs mouse survivalHigh metastatic potentialCalcium-dependent phospholipid-binding proteinMouse survivalPancreatic cancerDuctal adenocarcinomaEffective therapyProlonged survivalNovel molecular pathwaysANXA2 expressionSerum inhibitsMetastasisPhospholipid-binding proteinEMT processMetastatic potentialAntibody inhibitsPDA developmentNew targets
2010
EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors
Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, Olino K, Giday S, Fishman EK, Wolfgang CL, Edil BH, Makary M, Canto MI. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointestinal Endoscopy 2010, 73: 691-696. PMID: 21067742, DOI: 10.1016/j.gie.2010.08.030.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsRetrospective single-center cohort studySingle-center cohort studyMost pancreatic neuroendocrine tumorsCT detection rateMultidetector computerized tomographySensitivity of CTJohns Hopkins HospitalSensitivity of EUSDetection rateDetection of PNETsCT technologyCohort studyRole of EUSReferral biasPreoperative CTMultidetector CTComputerized tomographyNonrandomized designPancreatic imagingInsulinomaTumorsPatientsCT imagingImmuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)
Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surgery Today 2010, 40: 404-410. PMID: 20425541, DOI: 10.1007/s00595-009-4120-8.Peer-Reviewed Original ResearchConceptsCurrent treatment modalitiesNovel therapeutic approachesGene therapySurgical resectionTreatment arsenalTumor recurrenceCancer patientsTreatment modalitiesClinical trialsTherapeutic approachesGene therapeutic strategiesVivo modelCancerImmunotherapyTherapyFurther investigationPotential additionResectionChemotherapyPatientsRecurrenceMortalityTrialsCare
2009
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research 2009, 15: 4674-4679. PMID: 19584151, PMCID: PMC2819274, DOI: 10.1158/1078-0432.ccr-09-0227.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overFemaleGene DeletionHumansKaplan-Meier EstimateMaleMiddle AgedMutationPancreatic NeoplasmsPrognosisProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSmad4 ProteinTumor Suppressor Protein p53ConceptsPoor prognosisPancreatic cancerLymph node statusShorter overall survivalSMAD4 gene mutationUnderwent pancreaticoduodenectomyOverall survivalMargin statusNode statusTumor sizePatient outcomesPatientsAdenocarcinomaPancreasCancerPrognosisGene mutationsSMAD4 inactivationGene inactivationSomatic mutationsHomozygous deletionMonthsSurvivalGenetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer
Blackford A, Parmigiani G, Kensler TW, Wolfgang C, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Klein A, Cameron JL, Olino K, Schulick R, Winter J, Vogelstein B, Velculescu VE, Kinzler KW, Hruban RH. Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research 2009, 69: 3681-3688. PMID: 19351817, PMCID: PMC2669837, DOI: 10.1158/0008-5472.can-09-0015.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleGenes, p53Genes, rasGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationNeoplasm StagingPancreatic NeoplasmsSmokingConceptsPancreatic cancerCigarette smokingGenetic Mutations AssociatedSomatic mutationsPancreatic cancer genomeCigarette smokersSmoking accountsPancreatic carcinomaDiscovery screenSmokersCarcinomaSmokingCancerMutations AssociatedMutational patternsAdenocarcinomaDriver genesPancreasCigarettesMore mutationsMutationsNonsynonymous mutationsNonsmokersPrevious studiesIndividuals